Rare Pediatric Disease Research: O'Ryan Health Partners with Molecule Science Foundation
O'Ryan Health launches a community-funded philanthropic research programme for Juvenile Dermatomyositis, a rare autoimmune disease affecting children.
6 min read
Ella McCarthy-Page
Summary
- O'Ryan Health is leading a new research initiative to build the largest decentralized single-cell immune dataset for Juvenile Dermatomyositis (JDM), a rare and serious pediatric autoimmune condition, using its innovative Artemis platform for safe, at-home blood collection from children.
- Donors will receive one token for every $25 USD donation in either USD or USDC. Tokens can be used in the Coin-to-Company model as discussed in the project whitepaper.
The Rare Autoimmune Disease Affecting Children
Juvenile Dermatomyositis causes muscle weakness and skin rashes in children, driven by an immune system that turns against the body's own tissue. It is rare enough that assembling the large-scale, high-quality datasets needed to understand the disease has remained out of reach for most traditional research programmes. Samples are difficult to collect from pediatric patients, data sits in institutional silos, and funding mechanisms are poorly matched to the long timelines and uncertain outcomes that rare disease research demands. For the families living with JDM, these structural barriers translate into a simple, painful reality: not enough is known, and progress has been too slow.
O’Ryan Health’s Decentralized Health Technology
O'Ryan Health has built the Artemis platform to solve one of the most persistent challenges in pediatric research: patient access. Artemis enables families to collect small-volume blood samples from children at home s. Those samples are processed into high-resolution single-cell RNA sequencing datasets that serve as detailed digital models of a child's immune system, capturing how it responds as patients move through therapy tapering, immune flares, and enhanced treatment cycles. The immediate goal of this partnership is to generate data at scale and build the largest decentralized single-cell immune dataset for JDM; a resource that could reshape how this disease is understood, diagnosed, and ultimately treated.
As Dr. Tim Coleman, Architect of Operations at O'Ryan Health, put it; their Artemis platform truly embodies decentralized science.
Partnering with the Molecule Science Foundation and the Molecule Protocol
To bring this research to life, O'Ryan Health has partnered with Molecule Science Foundation, a US-based nonprofit aimed at facilitating community-funded science programmes through grants and Sponsored Research Agreements. Molecule Science Foundation operates independently from Molecule, the protocol and infrastructure layer for onchain science, though it leverages Molecule's technical and legal frameworks to structure its programmes.
About the author
Ella McCarthy-Page
BSc(Hons) in Biochemistry and Materials Science. A communicator working at the intersection of biotechnology and web3.
